You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

OXYTROL FOR WOMEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Oxytrol For Women patents expire, and what generic alternatives are available?

Oxytrol For Women is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in OXYTROL FOR WOMEN is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OXYTROL FOR WOMEN?
  • What are the global sales for OXYTROL FOR WOMEN?
  • What is Average Wholesale Price for OXYTROL FOR WOMEN?
Summary for OXYTROL FOR WOMEN
Drug patent expirations by year for OXYTROL FOR WOMEN
Drug Prices for OXYTROL FOR WOMEN

See drug prices for OXYTROL FOR WOMEN

Recent Clinical Trials for OXYTROL FOR WOMEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Astellas Scientific & Medical Affairs, Inc.
Christopher Patrick SmithPhase 3
BayerPhase 3

See all OXYTROL FOR WOMEN clinical trials

Pharmacology for OXYTROL FOR WOMEN

US Patents and Regulatory Information for OXYTROL FOR WOMEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OXYTROL FOR WOMEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ⤷  Sign Up ⤷  Sign Up
Abbvie OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ⤷  Sign Up ⤷  Sign Up
Abbvie OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for OXYTROL FOR WOMEN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva B.V.  Kentera (previously Oxybutynin Nicobrand) oxybutynin EMEA/H/C/000532
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Authorised no no no 2004-06-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for OXYTROL FOR WOMEN

See the table below for patents covering OXYTROL FOR WOMEN around the world.

Country Patent Number Title Estimated Expiration
Japan 2017008085 オキシブチニン治療に関連した有害な経験の最小化 (MINIMIZING ADVERSE EXPERIENCE ASSOCIATED WITH OXYBUTYNIN THERAPY) ⤷  Sign Up
Norway 20052625 ⤷  Sign Up
Japan 6209263 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OXYTROL FOR WOMEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0871420 CA 2005 00010 Denmark ⤷  Sign Up
0871420 05C0008 France ⤷  Sign Up PRODUCT NAME: OXYBUTININ; REGISTRATION NO/DATE: EU/1/03/270/001 20040615
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.